JPRN-jRCT2080221551未知2 期
Reducing Residual Albuminuria in Subjects with Diabetes & Nephropathy with Atrasentan - A Phase 2b, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety & Efficacy in Japanese Subjects
Abbott Japan Co., Ltd.0 个研究点目标入组 54 人开始时间: 2011年8月29日最近更新:
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patient has Type 2 diabetes and has been treated with at least one anti-hyperglycemic medication within the 12 months prior to the screening period.
- •-Patient is receiving a maximum tolerated labeled dose of an ACEi (Angiotensin Converting Enzyme inhibitor) or ARB (Angiotensin II Receptor Blocker)(Renin Angiotensin System (RAS) inhibitor).
- •-Estimated GFR (Glomerular Filtration Rate) is greater than or equal to 30 and less than or equal to 75 mL/min/1.73m2.
- •-UACR (Urinary Albumin to Creatinine Ratio) is greater than or equal to 200 mg/g as determined by the geometric mean of the three morning void urine specimens obtained at Run-in period.
- •-Serum albumin is greater than or equal to 3.0 g/dL.
- •-BNP (B-type Natriuretic Peptide) is less than or equal to 200 pg/mL.
- •-SBP (Systolic Blood Pressure) is greater than or equal to 110 mmHg and less than or equal to 160 mmHg.
- •-HbA1c (Glucosylated Hemoglobin A1c) is less than or equal to 12%.
- •-Serum potassium is less than or equal to 5.5 mEq/L.
排除标准
- •-Patient has a history of moderate or severe edema, facial edema unrelated to trauma, or a history of myxedema in the prior 6 months to screening.
- •-Patient is receiving loop diuretics greater than or equal to 120 mg QD (Once Daily) of furosemide or greater than or equal to 3.0 mg QD (Once Daily) of bumetanide or greater than or equal to 150 mg QD (Once Daily) of ethacrynic acid or greater than or equal to 60 mg QD (Once Daily) of torasemide.
- •-Patient has a documented history of Stage C or Stage D heart failure, defined ACC/AHA (American College of Cardiology/ American Heart Association Practice Guidelines).
- •-Patient is receiving any of a combination of an ACEi (Angiotensin Converting Enzyme inhibitor) and ARB (Angiotensin II Receptor Blocker) or rosiglitazone or aliskiren or an aldosterone antagonist.
- •-Patient is receiving pioglitazone and edema is present.
研究者
相似试验
已完成
2 期
Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With AtrasentanChronic Kidney DiseaseDiabetic NephropathyNCT01424319AbbVie (prior sponsor, Abbott)58
进行中（未招募）
1 期
Feasibility of aggressively lowering urine albumin in individuals with kidney biopsy-proven diabetic kidney disease - A Pilot StudyDiabetic Kidney DiseaseMedDRA version: 21.1Level: LLTClassification code 10012687Term: Diabetic renal diseaseSystem Organ Class: 100000004857EUCTR2021-001661-21-DKHerlev and Gentofte Hospital20
尚未招募
4 期
Comparing Medications for Reducing Kidney Damage in Diabetes: A Study on Dapagliflozin Alone and with EplerenoneCTRI/2024/01/061952Dr Nikhil Kumar
进行中（未招募）
1 期
Individual urinary protein decreasing effects of dapagliflozin in a remote clinical trial in patients with type 2 diabetes mellitus and elevated urinary protein concentrations.Patients with type 2 diabetes and albuminuria >20 mg/g (2.26 mg/mmol)EUCTR2020-004929-23-NLniversity Medical Center Groningen20
已完成
不适用
Individual albuminuria lowering response to dapagliflozin in a decentralized clinical trial in patients with type 2 diabetes mellitus and elevated albuminuriaAlbuminuria in patients with type 2 diabetes mellitus.100184241001265310029149NL-OMON50915niversitair Medisch Centrum Groningen20